Brian Rizzo

MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX’s work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions.  MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.